Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : FDA Denies Merck Request to Block Generic Form of Nasonex

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/19/2012 | 08:47pm CEST
   By Peter Loftus 
 

Merck & Co. (MRK) lost another round in its effort to block a competing generic copy of its Nasonex allergy nasal spray from entering the U.S. market.

The U.S. Food and Drug Administration this month denied Merck's petition asking the agency not to approve applications by generic drug makers to sell certain proposed generic forms of Nasonex. Merck, of Whitehouse Station, N.J., had argued the FDA shouldn't approve any proposed generic copy that has a different formulation than Nasonex.

The FDA denial of Merck's petition follows a federal court ruling earlier this year finding that Apotex Corp.'s proposed generic version of Nasonex doesn't violate a Merck patent for the drug. Merck has appealed that patent ruling.

Both developments remove some obstacles to the market entry of competing generic versions of Nasonex before patent protection expires in 2018, which would hurt sales of the branded drug. The drug, which Merck obtained in its 2009 purchase of Schering-Plough, generated $960 million in sales for the first nine months of 2012.

Canada's Apotex wants to sell a generic version of Nasonex that is slightly different from the original. The proposed Apotex product would have the same active ingredient, mometasone furoate, but in a non-water formulation, whereas Merck's product has a water component.

In 2009, Merck filed a patent-infringement lawsuit against Apotex in response to Apotex's application to market the generic product. Apotex argued that its proposed product wouldn't infringe upon Merck's patent because it would be a non-water formulation of mometasone furoate.

Following an April trial in federal court in Trenton, N.J., U.S. District Judge Peter G. Sheridan in June ruled that Apotex's proposed product wouldn't infringe upon the Merck patent, though the judge upheld the patent's validity. Merck has appealed the ruling.

In July, Merck filed a so-called citizen petition asking the FDA to refrain from approving any application for a non-water version of Nasonex that relies upon clinical data for the original drug. Merck argued that the non-water version couldn't be considered as the pharmaceutical equivalent to Nasonex because there would likely be differences in how they are absorbed in the body.

Lawyers for Apotex objected to Merck's request in a November comment letter to FDA, saying there was established precedent for the agency to approve generic versions of branded drugs that contain slightly different forms of the same active ingredient.

In a Dec. 7 letter, the FDA denied Merck's petition, saying that a non-water form of mometasone could potentially be considered pharmaceutically and therapeutically equivalent to the water-based Nasonex, assuming other requirements are met.

"We were disappointed with the decision on the citizen petition," said Merck spokesman Ronald Rogers.

The FDA denial of Merck's petition doesn't amount to approval of Apotex's generic product; that review is pending.

Apotex spokesman Steve Giuli declined to comment.

Merck shares declined 38 cents to $43.85 Wednesday.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/25 Merck KGaA and Pfizer break into cancer immunotherapy
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 MERCK : European Medicines Agency’s CHMP Recommends Approval of Merck&rsqu..
03/23 MERCK : Findings from Merck & Company in the Area of Pharmaceutical Science Repo..
03/23 MERCK : New Human Papillomavirus Findings from Merck & Company Reported (Develop..
03/23 MERCK : New Hypoglycemia Study Findings Have Been Reported by Investigators at M..
03/23 MERCK : StayWell Earns Re-accreditation From the National Committee for Quality ..
03/22 MERCK ANIMAL HEALTH : Completes Acquisition of Vallée S.A.
03/17 MERCK : Keytruda`s head-to-head against Opdivo rockets meds to Nos. 2 and 3 in a..
More news
Sector news : Pharmaceuticals - NEC
11:08pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
11:05pDJSHIRE : Files 8K - Other Events
07:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- Update
06:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing
06:27pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:52p Akcea Therapeutics Files For $100 Million IPO
03/27 BIOLINERX : Expands Cancer Pipeline Significantly By Acquiring Novel Drug Candid..
03/27 Will Trump Send Drug Stocks Tumbling Again?
03/27 Alzheimer's Cure Is Science's Holy Grail - Will Biogen Find It?
03/26 PRO PORTFOLIO PROOF II : David Katz 'Safer' Value Portfolio Picks
Advertisement
Financials ($)
Sales 2017 39 720 M
EBIT 2017 13 557 M
Net income 2017 8 404 M
Debt 2017 4 038 M
Yield 2017 2,98%
P/E ratio 2017 19,64
P/E ratio 2018 16,31
EV / Sales 2017 4,47x
EV / Sales 2018 4,32x
Capitalization 173 493 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,0 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.7.34%173 493
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
SANOFI7.76%117 163
More Results